Brief: Mereo Biopharma Provides Regulatory Updates On Alvelestat For Treatment Of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

Mereo BioPharma

21/03/2023 10:32

March 21 (Reuters) - Mereo Biopharma Group PLC
 MAH0y.F :
    * MEREO BIOPHARMA PROVIDES REGULATORY UPDATES ON ALVELESTAT
FOR
THE TREATMENT OF ALPHA-1-ANTITRYPSIN DEFICIENCY-ASSOCIATED LUNG
DISEASE
    * MEREO BIOPHARMA GROUP PLC - NO ADDITIONAL CONFIRMATORY
STUDY
REQUIRED
    * MEREO BIOPHARMA GROUP PLC - IS EXPLORING POTENTIAL
PARTNERSHIPS
TO FUND PHASE 3 STUDY
    * MEREO BIOPHARMA - DESIGNING SINGLE, GLOBAL, PHASE 3 STUDY
EVALUATING 240 MG DOSE OF ALVELESTAT VERSUS PLACEBO IN PATIENTS
WITH AATD-LD
    * MEREO BIOPHARMA - DESIGNING PHASE 3 STUDY EVALUATING 240
MG DOSE
OF ALVELESTAT TO SUPPORT APPLICATIONS FOR FULL MARKETING
APPROVALS IN U.S. & EU

Source text for Eikon:  ID:nGNXDMJ4c 
Further company coverage:  MAH0y.F 

 ((Reuters.Briefs@thomsonreuters.com;))